# A Phase II Study Using Rituximab Plus Venetoclax in the Front Line Treatment of Marginal Zone Lymphoma

> **NCT04416451** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 6 (actual)

## Conditions studied

- Marginal Zone Lymphoma

## Interventions

- **DRUG:** Rituximab
- **DRUG:** Venetoclax

## Key facts

- **NCT ID:** NCT04416451
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-05-04
- **Primary completion:** 2026-06
- **Final completion:** 2026-06
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2025-07-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04416451

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04416451, "A Phase II Study Using Rituximab Plus Venetoclax in the Front Line Treatment of Marginal Zone Lymphoma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04416451. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*